期刊文献+

三阴性乳腺浸润性导管癌的临床病理特征探讨 被引量:2

Pathological features of triple-negative invasive ductal carcinoma of breast
暂未订购
导出
摘要 目的:总结ER、PR、人表皮生长因子受体-2(HER-2)表达阴性(三阴性)乳腺浸润性导管癌患者的临床资料,了解其临床病理特征。方法:回顾性分析三阴性乳腺癌组(TNBC)和非三阴性乳腺癌组(non-TNBC)的组织学分级及淋巴结转移情况,了解三阴性乳腺浸润性导管癌的组织学分级和淋巴结转移特点。结果:TNBC组患者的中位年龄为39岁,有乳腺癌家族史者8例,占34.8%,组织学分级分别为Ⅰ级3例,Ⅱ级9例,Ⅲ级11例,淋巴结阳性转移率为19.5%,non-TNBC组患者发病平均年龄为48岁,有乳腺癌家族史者36例,占19.6%,组织学分级分别为Ⅰ级68例,Ⅱ级80例,Ⅲ级36例,淋巴结阳性转移率为22.4%。与non-TNBC组相比,TNBC组患者的中位年龄、组织学分级和淋巴结阳性转移率均明显不同,二者之间的差异有显著性意义,但就本组资料统计结果而言,尚不能认为乳腺癌家族史对TNBC的发生起重要作用,且TNBC组的淋巴结转移率低于non-TNBC组。结论:三阴性乳腺浸润性导管癌是一种高危乳腺癌,多发于较年轻的患者,其组织学分级多为高级别。 Objective: To summarize the pathological features of triple-negative invasive ductal car cinoma of breast. Methods: Histological grade and lymph node metastasis of triple negative breast cancer (TNBC, A group) and non triple negative breast cancer patients (non TNBC, B group) were retrospec tively analyzed. Results The median age of patients of TNBC was 39 years old, and 8 cases (34. 8%, 8/23) had family history of breast cancer. Three cases in TNBC group were at grade Ⅰ , 9 cases at grade Ⅱ and 11 cases at grade Ⅲ, respectively; and the ratio of lymph node metastasis was 19.5%. The median age of patients of non-TNBC was 48 years, and 36 cases (19.6%,36//184) had family history. 68 cases in non-TNBC were at grade Ⅰ , 80 cases at grade Ⅱand 36 cases at grade Ⅲ and the ratio of lymph node metastasis was 22.4%. There were significant differences in median age, histological grade and lymph node metastasis in two groups. Conclusions: Triple negative invasive ductal carcinoma of breast is highly risk, and occurs mainly in younger patients, with more higher histological grade level.
出处 《海南医学院学报》 CAS 2010年第11期1409-1411,1415,共4页 Journal of Hainan Medical University
基金 海南医学院科研基金资助学报项目(0020100387)~~
关键词 乳腺浸润性导管癌 三阴性乳腺癌 组织学分级 Invasive ductal carcinoma of breast TNBC Histological grade
  • 相关文献

参考文献5

二级参考文献30

  • 1曹亚丽,吴晓波,王忆丽,瞿伟,涂剑宏,雷秋模.乳腺癌组织中c-erbB-2、p53、PCNA和nm23蛋白的表达及其临床意义[J].中国肿瘤临床与康复,2005,12(3):208-211. 被引量:11
  • 2杨丽芳,宋三泰,李晓兵,江泽飞,刘晓晴,马维娜,乔西平,郭斯启.284例原发乳腺癌c-erbB2蛋白的表达及其与预后的关系[J].中华肿瘤杂志,2006,28(4):294-297. 被引量:11
  • 3Carey LA, Perou CM, Livasy CA, et al. Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study [J]. JAMA, 2006, 295 (21): 2492-2502.
  • 4Harvey JM, Clark GM, Osborne CK, et al. Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer [J]. J Clin Oncol, 1999,17:1474-1481.
  • 5Kaaks R, Rinaldi S, Key T J, et al. Postmenopausal serum androgens, oestrogens and breasf cancer risk: the European prospective investigation into cancer and nutrition [J]. Endocr Rerat Cancer, 2005,12 (4): 1071-1082.
  • 6Tworoger SS, Missmer SA, Eliassen AH, et al. The association of plasma DHEA and DHEA sulfate with breast cancer risk in predominantly premenopausal women [J]. Cancer Epidemiol Biomarkers Prev, 2006,15 (5):967-971.
  • 7Wong YC, Xie B. The role of androgens in mammary carcinogenesis [J]. Ital J Anat Embryol, 2001,106(2 Suppl 1):111-125.
  • 8Bryan RM, Mercer R J, Bennett RC, et al. Androgen receptors in breast cancer [J]. Cancer, 1984,54:2436-2440.
  • 9Agoff SN, Swanson PE, Linden H, et al. Androgen receptor expression in estrogen receptor-negative breast cancer. Immunohistochemical, clinical, and prognostic associations [J]. Am J Clin Pathol, 2003, 120 (5):725- 731.
  • 10Gonzalez LO, Cortel MD, Vazquez J, et al. Androgen receptor expresion in breast cancer: Relationship with clinicopathological characteristics of the tumors, prognosis, and expression of metalloprotenases and their inhibitors [J]. BMC Cancer, 2008,8:149.

共引文献41

同被引文献24

引证文献2

二级引证文献9

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部